On this page
LISSUN raises ₹48 crore to double Sunshine therapy-centre network to 50
Our read
LISSUN's biggest second-order opportunity is not simply doubling centres: a denser Sunshine network could become a scalable referral and care-delivery platform for pediatric developmental services, provided clinical talent supply does not become the limiting factor.
For operators
LISSUN’s plan to add 25 Sunshine therapy centres by next year signals accelerating demand for child-development services and raises the bar for scalable, tech-enabled care delivery.
Watch
Announcements of city-level centre locations, lease commitments and the opening cadence needed to reach 50 centres by next year.
Ask next
The report,
Gurugram-based LISSUN raised ₹48 Cr in Series A funding led by Colossa Ventures. It will expand its Sunshine child-development and therapy network from 25 to 50 centres by next year, while investing in AI-led tools and clinical processes.
Store and format facts
From the report. Source details below
- 10,000+ therapy sessions per month
- ₹45 Cr initially reported funding target
Other figures
- ₹48 Cr ($5 Mn) Series A
Next on the rollout
- Net therapist hiring, attrition, clinician-to-centre ratios and evidence of specialized talent shortages.
- New-centre utilization, appointment wait times, repeat-session rates and centre-level break-even timelines.
- Partnerships with schools, hospitals, pediatric networks, insurers or corporate health-benefit providers.
- Evidence that AI tools reduce administrative time, improve clinical documentation consistency or lift sessions per therapist.
The counter-case
The case against this reading — not reported by the source.
Doubling a therapy-centre network in roughly a year is more an execution and clinician-supply challenge than a capital challenge. ₹48 crore may be insufficient once leases, fit-outs, hiring, therapist training, local marketing and pre-opening losses are accounted for. Rapid expansion could dilute clinical quality, increase therapist churn and create underutilised centres if referral pipelines and paying demand do not scale in tandem. AI-led clinical tooling may add compliance, data-privacy and adoption risks without materially improving unit economics.
The source
First seen